Friday, April 26, 2024
Home Biotech News Exsosomes

Exsosomes

    Random

    Heads Up! Big News on Stem Cells & Covid This Weekend.

    Stem Cells Editor / Curator -
    Gentlemen Start Your Research Engines! Be Fast and Be Early. We Could be Looking at a "Beam Me Up Scotty" Type Vector...

    Adding Brainstorm Therapeutics (BCLI) $4.59 to CoronaVirus Watchlist.

    Exsosomes Editor / Curator -
    This is a company exploring the use of stem cells for a number of ailments. The lead program is (or was) for...
    Biotech Stock Review, Exsosomes

    Exosomes, Extracellular Vesicles, and the CoronaVirus.

    Biotech News Editor / Curator -
    Uploading a Series of Articles on Extracellular Vesicles, Including Potential Effects on the CoronaVirus and ARDS. Article #1:...
    Organicell

    Organicell (BPSR) a Triple Since Easter.

    Infections Editor / Curator -
    Slowly she turns, step-by-step. $20 million gain in market value. Spurred by FDA Emergency IND's. RELATED: Adding Organicell (BPSR)...

    Latest article

    GeoVax (GOVX) Launches Vaccine Manufacturing System.

    2024 Watch List Editor / Curator -
    GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System Manufacturing Process for Phase 3 and Commercial Production...

    Experts From Harvard, Scripps Research Institute, the University Hospital Zürich, and the Former Chief...

    All News Editor / Curator -
    Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody...

    Major Mpox Outbreak in the Democratic Republic of Congo.

    Mpox Editor / Curator -
    As Reported in NPR's Gates and Soda Major Mpox Outbreak in the Democratic Republic of Congo is a...
    The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
    Contact us: [email protected]
    © Managed by Revelers.IO Media Group Inc.